Literature DB >> 23359771

Effects of anastrozole combined with Shuganjiangu decoction on osteoblast-like cell proliferation, differentiation and OPG/RANKL mRNA expression.

Yan Ren1, Shu-Yan Han, Ping-Ping Li.   

Abstract

OBJECTIVE: To investigate the effects of anastrozole combined with Shuganjiangu decoction on osteoblast-like cells.
METHODS: Human osteoblast-like cells MG-63 were cultured and divided into four groups: control, anastrozole, Shuganjiangu decoction (SGJGD), and anastrozole combined with SGJGD. Cell proliferation was investigated by MTT assay. Alkaline phosphatase (ALP) and osteocalcin, the indicators of cell differentiation, were evaluated by p-nitrophenyl- phosphate method and radioimmunoassay, respectively. Gene expressions of ALP, osteocalcin, osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL) were examined by real-time PCR.
RESULTS: As evidenced by MTT assay, cell proliferation of MG-63 was inhibited by anastrozole, but stimulated with treatment of SGJGD alone and combined with anastrozole (P<0.01). Compared with control group, ALP activity was increased by the treatment of SGJGD alone and combined with anastrozole (P<0.01). Also, osteocalcin secretion was enhanced with the treatment of SGJGD single and combination with anastrozole (P<0.05). In the real-time PCR assay, gene expressions of ALP and osteocalcinwere significantly increased (P<0.01 for ALP, P<0.05 for osteocalcin) by the treatment of SGJGD and anastrozole combined with SGJGD, but the expression of RANKL was decreased (P<0.05). Moreover, anastrozole combined with SGJGD upregulated gene expression of OPG (P<0.01).
CONCLUSION: SGJGD may alleviate the injury effects of anastrozole on MG-63 cells through adjusting bone formation and resorption indicators.

Entities:  

Keywords:  Shuganjiangu decoction; alkaline phosphatase; osteoblast-like cell; osteocalcin; osteoprotegerin; receptor activator of nuclear factor kappa B ligand (RANKL)

Year:  2012        PMID: 23359771      PMCID: PMC3555266          DOI: 10.1007/s11670-012-0151-6

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  28 in total

1.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.

Authors:  Guitty Eghbali-Fatourechi; Sundeep Khosla; Arunik Sanyal; William J Boyle; David L Lacey; B Lawrence Riggs
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 2.  Endocrine therapy for breast cancer: an overview.

Authors:  K L Cheung
Journal:  Breast       Date:  2007-05-14       Impact factor: 4.380

3.  Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.

Authors:  Husheem Michael; Pirkko L Härkönen; H Kalervo Väänänen; Teuvo A Hentunen
Journal:  J Bone Miner Res       Date:  2005-08-01       Impact factor: 6.741

4.  Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

Authors:  Ian E Smith; Mitch Dowsett; Stephen R Ebbs; J Michael Dixon; Anthony Skene; J-U Blohmer; Susan E Ashley; Stephen Francis; Irene Boeddinghaus; Geraldine Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

5.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

Review 6.  Aromatase inhibitors and bone loss.

Authors:  Edith A Perez; Katherine Weilbaecher
Journal:  Oncology (Williston Park)       Date:  2006-08       Impact factor: 2.990

7.  Human bone cell cultures in biocompatibility testing. Part II: effect of ascorbic acid, beta-glycerophosphate and dexamethasone on osteoblastic differentiation.

Authors:  M J Coelho; M H Fernandes
Journal:  Biomaterials       Date:  2000-06       Impact factor: 12.479

Review 8.  The role of aromatase inhibitors in the treatment of metastatic breast cancer.

Authors:  Henning Mouridsen; Michael Gershanovich
Journal:  Semin Oncol       Date:  2003-08       Impact factor: 4.929

Review 9.  Fracture risk assessment in postmenopausal women.

Authors:  Ronald C Hamdy
Journal:  Rev Endocr Metab Disord       Date:  2010-12       Impact factor: 6.514

Review 10.  Biology of RANK, RANKL, and osteoprotegerin.

Authors:  Brendan F Boyce; Lianping Xing
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.